Companies nearing the end of the FDA path

There is a nice-sized list of Bay Area companies nearing the end (presumably) of the FDA path toward approval. Among them:
WARREN BUFFET SAID ...

• Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) of Mountain View — Feb. 4 approval date for Adasuve for agitation in patients with schizophrenia;

• NeurogesX Inc. (NASDAQ: NGSX) of San Mateo — Feb. 9 FDA panel for Qutenza in HIV-related pain where the nerves don’t work properly. NeurogesX also is looking at a March 7 FDA approval date for Qutenza;
  
• Corcept Therapeutics Inc. (NASDAQ: CORT) of Mountain View — Feb. 17 approval date for the Cushing’s Symdrome treatment Corlux;

• Vivus Inc. (NASDAQ: VVUS) of Mountain View — Feb. 22 FDA advisory panel for Qnexa for obesity;

• Genentech Inc. of South San Francisco and Curis Inc. (NASDAQ: CRIS) of Lexington, Mass. — March 8 approval date for vismodegib, a treatment for advanced basal cell carcinoma;

• MAP Pharmaceuticals Inc. (NASDAQ: MAPP) of Mountain View — March 26 approval date for Levadex in migraines;

• Affymax Inc. (NASDAQ: AFFY) of Palo Alto — March 27 approval date for peginesatide for anemia in kidney dialysis patients.

Volume : Price Trends ...


Pending FDA Drug Approval Decisions:
Jan. 27: Amylin Pharmaceuticals'(AMLN_) Bydureon for diabetes.
Feb. 14: BioSante Pharmaceuticals'(BPAX_) Bio-T-Gel for hypogonadism.
Feb. 17: Corcept Therapeutics'(CORT_) Corlux for Cushing's sydrome.
Feb. 26: Columbia Labs'(CBRX_) Prochieve for reduction of risk of preterm birth.
March 6: Discovery Labs'(DSCO_) Surfaxin for respiratory distress syndrome.
March 6: Astex Pharmaceuticals'(ASTX_) Dacogen for acute myeloid leukemia.
March 7: Neurogesx'(NGSX_) Qutenza for HIV-related nerve pain.
March 8: Roche and Curis'(CRIS_) vismodegib for basal cell carcinoma.
March 26: MAP Pharmaceuticals'(MAPP_) Levadex for migraines.
March 27: Affymax's(AFFY_) peginesatide for anemia due to chronic kidney disease.
March 28: Chelsea Therapeutics'(CHTP_) Northera for orthostatic hypotension.
April 17: Vivus'(VVUS_) Qnexa for obesity.
April 18: Vertex Pharmaceuticals'(VRTX_) Kalydeco for cystic fibrosis
April 24: Cell Therapeutics'(CTIC_) pixantrone for non-Hodgkin's lymphoma
April 26: Amgen's(AMGN_) Xgeva for prevention or delay of spread of prostate cancer to bone.
April 27: Vivus'(VVUS) avanafil for erectile dysfunction.